Qyuns Therapeutics Co., Ltd. (HKG:2509)

Hong Kong flag Hong Kong · Delayed Price · Currency is HKD
15.40
+0.64 (4.34%)
Jul 17, 2025, 11:56 AM HKT
-28.70%
Market Cap3.28B
Revenue (ttm)168.98M
Net Income (ttm)-357.11M
Shares Out222.07M
EPS (ttm)-1.63
PE Ration/a
Forward PEn/a
Dividendn/a
Ex-Dividend Daten/a
Volume205,400
Average Volume143,540
Open14.98
Previous Close14.76
Day's Range14.86 - 15.48
52-Week Range5.95 - 30.95
Betan/a
RSI48.46
Earnings DateAug 15, 2025

About Qyuns Therapeutics

Qyuns Therapeutics Co., Ltd., a clinical-stage biotech company, focuses on the research and development of biologic therapies for autoimmune and allergic diseases in the People’s Republic of China. Its lead product candidates include QX002N, an interleukin (IL)-17A inhibitor in Phase III clinical trial for the treatment of ankylosing spondylitis; and QX005N, a monoclonal antibody (mAb) blocking IL-4Ra, which is in Phase III clinical trial for the treatment of prurigo nodularis. The company also commercializes QX001S, which is an IL-12/L-23p49 i... [Read more]

Industry Biotechnology
Sector Healthcare
Founded 2015
Employees 339
Stock Exchange Hong Kong Stock Exchange
Ticker Symbol 2509
Full Company Profile

Financial Performance

Financial numbers in CNY Financial Statements

News

There is no news available yet.